Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) insider Irene Becklund sold 10,668 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $5.68, for a total value of $60,594.24. Following the completion of the transaction, the insider now directly owns 6,978 shares in the company, valued at approximately $39,635.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Irene Becklund also recently made the following trade(s):
Get Hims & Hers Health alerts:- On Friday, September 9th, Irene Becklund sold 11,002 shares of Hims & Hers Health stock. The shares were sold at an average price of $6.64, for a total value of $73,053.28.
- On Tuesday, July 5th, Irene Becklund sold 19,331 shares of Hims & Hers Health stock. The shares were sold at an average price of $5.00, for a total value of $96,655.00.
Hims & Hers Health Trading Down 3.7 %
Shares of HIMS opened at $5.47 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $2.72 and a fifty-two week high of $9.19. The firm has a 50-day simple moving average of $6.22 and a 200-day simple moving average of $5.10.
Hims & Hers Health (NYSE:HIMS – Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Hims & Hers Health had a negative net margin of 22.22% and a negative return on equity of 23.24%. The business had revenue of $113.60 million during the quarter, compared to the consensus estimate of $103.89 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. The business's quarterly revenue was up 89.0% compared to the same quarter last year. Equities research analysts predict that Hims & Hers Health, Inc. will post -0.36 earnings per share for the current fiscal year.Wall Street Analyst Weigh In
HIMS has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $7.00 to $8.00 in a report on Wednesday, August 10th. Guggenheim raised their price objective on Hims & Hers Health to $12.00 in a report on Monday, August 15th. Credit Suisse Group raised their price objective on Hims & Hers Health from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Wednesday, August 10th. Piper Sandler dropped their price objective on Hims & Hers Health from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Thursday, May 26th. Finally, SVB Leerink raised their price objective on Hims & Hers Health from $4.00 to $5.00 and gave the stock an "underperform" rating in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $7.38.
Institutional Investors Weigh In On Hims & Hers Health
Several hedge funds have recently made changes to their positions in HIMS. Raymond James & Associates acquired a new stake in Hims & Hers Health in the fourth quarter valued at about $205,000. HighTower Advisors LLC lifted its position in Hims & Hers Health by 14.4% in the fourth quarter. HighTower Advisors LLC now owns 31,761 shares of the company's stock valued at $209,000 after purchasing an additional 3,998 shares during the period. Teacher Retirement System of Texas lifted its position in Hims & Hers Health by 25.6% in the fourth quarter. Teacher Retirement System of Texas now owns 14,808 shares of the company's stock valued at $97,000 after purchasing an additional 3,022 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Hims & Hers Health in the fourth quarter valued at about $237,000. Finally, PEAK6 Investments LLC lifted its position in Hims & Hers Health by 18.3% in the fourth quarter. PEAK6 Investments LLC now owns 138,866 shares of the company's stock valued at $910,000 after purchasing an additional 21,526 shares during the period. Institutional investors and hedge funds own 43.41% of the company's stock.
Hims & Hers Health Company Profile
(Get Rating)
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Featured Stories
- Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.